

Statement by Blue Earth Diagnostics on COVID-19

Commitment in the Face of COVID-19

At Blue Earth Diagnostics, we develop and provide PET diagnostic imaging and therapeutic radiopharmaceutical products to help people with serious disease such as cancer. COVID-19 has brought unprecedented changes to our world, and our hearts go out to everyone who has been affected by this disease. Amid the challenges, Blue Earth Diagnostics stands committed to supporting those parts of life that matter most: health and well-being.

The health and safety of Blue Earth Diagnostics employees and our communities is our first and foremost priority.

To continue limiting the spread of COVID-19, we are doing all that we can to support patients, healthcare professionals, our employees, their families and loved ones, and the communities where we live and work. Our actions are informed by national health and disease control organization guidelines, geographically-specific legislation, science, and thoughtfully considered, people-centric approaches. We provide our employees with guidance and information regarding appropriate safety measures relating to meetings, travel restrictions, remote working policies, and health and safety.

Our sincere appreciation goes out to all healthcare professionals who fight serious disease and help to protect public health.

Healthcare professionals and the entire healthcare workforce continue to fearlessly put themselves on the front lines in battling COVID-19. We share our deepest thanks to everyone who is engaged in selfless efforts to help patients and protect the health of our communities. Blue Earth Diagnostics is committed to ensuring that we continue to support healthcare professionals.

We empathize with patients, who face the biggest challenges in the COVID-19 landscape.

The needs of all patients are particularly acute during the COVID-19 pandemic. Patients with cancer face additional anxiety and stress. Many may be vulnerable and have concerns about personal safety in entering a healthcare facility where they could be exposed to COVID-19. Others may be concerned about signs of potential changes in their condition, and whether access to PET scan procedures that can inform medical decision-making management may be limited. Blue Earth Diagnostics is doing its utmost to ensure that patients with serious disease can continue to have access to PET scans that may help guide decisions about their care. We work actively with advocacy groups to help support patients coping with added challenges imposed by COVID-19.

We remain committed to ensuring that products are readily available for physicians and patients.

We work closely with our manufacturers, distributors and other trusted partners to manage and monitor supply chain activities, and foresee no impact resulting from COVID-19 at this time. Blue Earth Diagnostics is in regular contact with customers, study investigators and clinical research organizations to assess their potential needs. We have implemented production flexibility in specific geographies as conditions warrant, to address the needs of healthcare facilities and patients

Amid the challenges of COVID-19, we have hope, and we look to the future.

The horizon of hope in overcoming COVID-19 is broadening, and we are optimistic that it will continue to expand as vaccine availability increases and therapeutic solutions emerge. Blue Earth Diagnostics is ready. We are implementing selective and well-considered re-opening activities in full accordance with national, regional, and local requirements, as well as those of individual institutions. All of our re-opening activities are being conducted with consideration of the safety and health of our employees, their families and loved ones, patients, healthcare workers and communities top of mind. We understand the important decisions that patients with cancer may be making as PET scans that may have been delayed are rescheduled. We want you to know that we will be here if, and whenever, you are ready.

At our core, Blue Earth Diagnostics is all about helping patients. We continue to work tirelessly toward that goal so that more people can enjoy health and well-being.